Retina-The Journal of Retinal and Vitreous Diseases最新文献

{"title":"Adjuvant Anti-VEGF Therapy During Ablative Treatment for Coats Disease: A Systematic Review and Meta-Analysis.","authors":"Charles Zhang, Nicholas Leung, Baltaj Sandhur, Daniel Zhu, Joaquin Sosa-Lockward, Nicolas A Yannuzzi, Basil K Williams, Hong-Uyen Hua, Audina M Berrocal","doi":"10.1097/IAE.0000000000005008","DOIUrl":"https://doi.org/10.1097/IAE.0000000000005008","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy and safety of adjunctive intravitreal anti-vascular endothelial growth factor (VEGF) therapy combined with standard ablative treatment in Coats disease.</p><p><strong>Methods: </strong>A search of PubMed, Embase, and SCOPUS was conducted to identify studies comparing ablative therapy alone versus ablative therapy with anti-VEGF for Coats disease. Five studies (136 eyes treated with ablation alone and 82 with combination therapy) were included. Data on treatment sessions, quiescence, visual acuity (VA) and tractional retinal detachment (TRD) were extracted.</p><p><strong>Results: </strong>Adjunctive anti-VEGF significantly reduced the treatment sessions required to achieve quiescence (Mean difference [MD] 0.47 sessions, 95% confidence interval [CI] 0.10-0.85, p = 0.01). No significant difference was found in anatomic outcomes with both groups having a similar number of eyes which resulted in phthisis. No significant difference was found in the BCVA at final follow up (MD = 0.20, 95% CI -0.20 to 0.59, p = 0.33) without significant heterogeneity (I2 =23%, p = 0.28). Eyes with adjunctive anti-VEGF were not found to be associated with a significantly higher risk of TRD (RR 2.64, 95% CI 0.34-20.30, p = 0.35). Due to the retrospective design of the included studies, the overall grade of evidence was deemed low.</p><p><strong>Conclusions: </strong>Adjunctive anti-VEGF therapy may reduce the total treatment burden while achieving similar anatomical and functional outcomes. In addition, there appears to be no significant increase in the risk of TRD. Judicious use of anti-VEGF may be a useful therapy to consider in patients with Coats disease requiring ablative therapy.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148914366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Vascular Risks After Retinal Artery and Vein Occlusions: A Large-Scale Real-World Analysis.","authors":"Tzu Jui Wang, Michael Zhu, Ishani Kapoor, Nolan Ziemniak, Patrick Vespa, Caleb Hansel, Astha Sahoo, Majda Hadziahmetovic","doi":"10.1097/IAE.0000000000005007","DOIUrl":"https://doi.org/10.1097/IAE.0000000000005007","url":null,"abstract":"<p><strong>Purpose: </strong>To compare systemic vascular disease risk among central and branch retinal artery occlusion (CRAO, BRAO) and central and branch retinal vein occlusion (CRVO, BRVO).</p><p><strong>Methods: </strong>This retrospective cohort study used TriNetX to compare hazard ratios (HR) for ischemic stroke (IS), ischemic heart disease (IHD), myocardial infarction (MI), atrial fibrillation (AF), and mortality among 129,468,002 patients with CRAO, CRVO, BRAO, or BRVO diagnosed between January 1, 2015, and July 5, 2026, using propensity score-matched data.</p><p><strong>Results: </strong>Retinal artery occlusions (RAO) were associated with significantly higher risks of all measured outcomes than retinal vein occlusions (RVO), including IS (HR, 1.954), IHD (HR, 1.368), MI (HR, 1.313), AF (HR, 1.530), and mortality (HR, 1.299) (all P<0.0001). BRAO carried higher risk than BRVO across all outcomes. CRAO carried higher risk than BRAO for MI and mortality only, and higher risk than CRVO across all outcomes, most strongly for IS (HR, 2.259). CRVO carried higher mortality risk than BRVO, with no significant difference in other outcomes.</p><p><strong>Conclusion: </strong>Retinal artery occlusions have a substantially greater systemic vascular risk than retinal vein occlusions. This supports urgent systemic evaluation following retinal arterial occlusion, particularly CRAO, to identify patients at highest risk for life-threatening thromboembolic events.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ENDOPHTHALMITIS INCIDENCE AFTER VITRECTOMY: A Systematic Review and Meta-Analysis of Risk Factors and Prevention Strategy.","authors":"Robert McGrath, Liam Mulcahy, Abdulrahman Al Abri, Shane Whitlow, Nicholas Brennan, Paul Connell","doi":"10.1097/IAE.0000000000004810","DOIUrl":"10.1097/IAE.0000000000004810","url":null,"abstract":"<p><strong>Purpose: </strong>Consensus is lacking on best practice to minimize endophthalmitis rates after vitrectomy. This review examines all available literature to determine the incidence of postvitrectomy endophthalmitis and associated risk-reduction strategies.</p><p><strong>Methods: </strong>A comprehensive literature search was performed for endophthalmitis incidence after vitrectomy. Meta-analysis was performed comparing risk factors for endophthalmitis: instrument gauge, prophylactic antibiotics, phacovitrectomy, and intraocular tamponade.</p><p><strong>Results: </strong>We identified 69 studies which reported 2,781 cases of endophthalmitis after 1,979,160 vitrectomies (0.14%). Meta-analysis found that smaller-gauge vitrectomy had a nonsignificantly higher risk of endophthalmitis compared with 20-gauge surgery (OR 2.09, 95% CI 0.88-5.0). Endophthalmitis rates were significantly higher with 25-gauge compared with 23-gauge instruments (OR 2.03, 95% CI 1.05-3.92). Prophylactic subconjunctival antibiotic use did not decrease the risk of endophthalmitis compared with topical antibiotics (OR 0.77, 95% CI 0.36-1.64). Phaco-vitrectomy did not increase the endophthalmitis risk (OR 1.17, 95% CI 0.81-1.70). The use of intraocular tamponade other than fluid was associated with significantly lower rates of endophthalmitis (OR 0.15, 95% CI 0.09-0.27).</p><p><strong>Conclusion: </strong>The incidence of endophthalmitis was higher than in previous reviews. Nonfluid intraocular tamponade significantly reduced the incidence of endophthalmitis but subconjunctival antibiotics did not. Small-gauge vitrectomy and phacovitrectomy were not associated with significantly higher rates of endophthalmitis.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"1465-1477"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146222169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EFFICACY OF COMBINED DEXAMETHASONE IMPLANT AND NAVIGATED SUBTHRESHOLD MICROPULSE YELLOW LASER IN DIABETIC MACULAR EDEMA.","authors":"Giovanni William Oliverio, Alessandro Meduri, Irene Ingrande, Pasquale Aragona","doi":"10.1097/IAE.0000000000004843","DOIUrl":"10.1097/IAE.0000000000004843","url":null,"abstract":"<p><strong>Purpose: </strong>To compare functional and anatomical outcomes of combining intravitreal dexamethasone implant (DEX-I) (Ozurdex) with navigated subthreshold yellow (577 nm) micropulse laser (subthreshold micropulse laser treatment [SMLT]) versus dexamethasone monotherapy in diabetic macular edema.</p><p><strong>Methods: </strong>In this prospective randomized study, 80 eyes with center-involving diabetic macular edema were allocated to two groups: 40 eyes received DEX-I followed 4 weeks later by navigated SMLT (DEX-I + SMLT), and 40 eyes received DEX-I alone (DEX-I). Best-corrected visual acuity (Early Treatment Diabetic Retinopathy Study - ETDRS letters), central subfield thickness, and ETDRS subfield thicknesses were measured at baseline and at 2, 4, 6, 9, and 12 months. Reinjection-free survival was analyzed over 12 months.</p><p><strong>Results: </strong>At 6 months, mean best-corrected visual acuity improvement was greater in the DEX-I + SMLT group than in the DEX-I monotherapy group (6.2 ± 5.1 vs. 4.1 ± 6.4 letters; P = 0.03), and this difference persisted at 12 months (5.8 ± 6.5 vs. 3.6 ± 6.8 letters; P = 0.05). Mean central subfield thickness was lower in the DEX-I + SMLT group at 6 months (295 ± 46 vs. 321 ± 58 µ m; P = 0.02) and remained lower at 12 months (315 ± 60 vs. 342 ± 70 µ m; P = 0.05). Median retreatment-free survival was longer in the combination group (11.2 vs. 8.3 months).</p><p><strong>Conclusion: </strong>Within the 12-month follow-up period, sequential navigated SMLT performed 4 weeks after dexamethasone implantation was associated with improvements in visual and anatomical outcomes and with a longer retreatment-free interval compared with dexamethasone monotherapy, without additional safety concerns.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"1540-1547"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147516840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DEXAMETHASONE IMPLANT AND AFLIBERCEPT COMBINATION THERAPY VERSUS AFLIBERCEPT MONOTHERAPY FOR DIABETIC MACULAR EDEMA: A Prospective, Comparative Trial (COED Trial).","authors":"Irene Park Kim, Christine Orndahl, Caroline Nyaiburi, Rajiv Anand, David Callanan, Deborah Chong, Lori Coors, Timothy Fuller, Andrew McClellan, Wayne Solley, Robert Wang, Patrick Williams, Yoshihiro Yonekawa, Ashkan Michael Abbey","doi":"10.1097/IAE.0000000000004858","DOIUrl":"10.1097/IAE.0000000000004858","url":null,"abstract":"<p><strong>Purpose: </strong>To compare combined dexamethasone implant and intravitreal aflibercept (AFB) to AFB monotherapy treatment in diabetic macular edema (DME).</p><p><strong>Methods: </strong>This open-label randomized clinical trial involved randomization of patients with DME (n = 50) to pro re nata treatment with combined dexamethasone and AFB or AFB alone according to prespecified retreatment criteria. Best-corrected visual acuity, central subfield retinal thickness (CST), and adverse events were monitored monthly for 48 weeks.</p><p><strong>Results: </strong>The combined treatment and the AFB monotherapy group demonstrated CST reductions at each visit. The difference (95% confidence intervals [CI]) in the change from baseline in CST between the groups was -32.9 (-81.5 to 15.6) µ m at week 48, favoring the combination therapy group without significance ( P = 0.183). The difference in the change from baseline in best-corrected visual acuity was -3.3 (-9.2 to 2.5) letters read at week 48 ( P = 0.266). Injection number was numerically higher in the aflibercept monotherapy group (mean ± SD, 5.9 ± 1.8) than in the combination group (4.9 ± 1.5). The AFB monotherapy group had a 90% higher injection rate over the study period (incidence rate ratio [95% CI] = 1.9 [0.9-4.0]) without statistical significance ( P = 0.081). The combined treatment group achieved quicker time to resolution of DME (log-rank P -value = 0.013) by a median difference (95% CI) of 12 (0-24) weeks. Three eyes and two eyes in the combined therapy group developed worsening cataracts and intraocular pressure elevation requiring medical management, respectively.</p><p><strong>Conclusion: </strong>Combined treatment achieved similar anatomic and visual outcomes compared with AFB monotherapy, with quicker DME resolution but higher cataract and intraocular pressure risks.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"1520-1531"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147640610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PERIVASCULAR MULTIFOCAL CHOROIDITIS WITH PANUVEITIS: Clinical and Multimodal Imaging Features.","authors":"Alessandro Feo, Alberto Quarta, Demi A Miller, Sapna Gangaputra, David Sarraf, Edmund Tsui","doi":"10.1097/IAE.0000000000004880","DOIUrl":"10.1097/IAE.0000000000004880","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the long-term clinical and imaging features of the perivascular phenotype of multifocal choroiditis with panuveitis.</p><p><strong>Methods: </strong>Retrospective observational case series of eight patients (14 eyes) diagnosed with perivascular multifocal choroiditis with panuveitis at tertiary uveitis referral centers. Clinical data and multimodal imaging-including ultra-widefield color fundus photography (CFP), fundus autofluorescence (FAF), fluorescein angiography (FA), indocyanine green angiography, optical coherence tomography (OCT), and OCT angiography-were reviewed at all available visits, with analyses focused on baseline and final follow-up visits. A comprehensive systemic work-up was performed to exclude infectious, autoimmune, and neoplastic etiologies.</p><p><strong>Results: </strong>Median age at presentation was 27 years (interquartile range, 17-51), with a median follow-up of 5.4 years (interquartile range, 3-10.1). Disease was bilateral in 6 of 8 patients (75%). Lesions demonstrated a reproducible perivascular distribution along retinal arteries and veins, frequently extending into the mid- and far-periphery. On CFP and FAF, lesions appeared as pigmented, hypoautofluorescent spots evolving into sharply demarcated atrophic scars. FA showed late hyperfluorescent staining without leakage. OCT revealed outer retinal and retinal pigment epithelium disruption, subretinal hyperreflective material, vertical hyperreflective column bridging the subretinal hyperreflective material and overlying retinal vessels, and progression to atrophy. Infectious and inflammatory evaluations were negative in all cases. Mild, transient anterior segment or vitreous inflammation was observed in a minority of eyes. Median BCVA remained stable at 20/25 (interquartile range, 20/32-20/20). Choroidal neovascularization occurred in 3 of 14 eyes (21%) and responded to antivascular endothelial growth factor therapy.</p><p><strong>Conclusion: </strong>Perivascular multifocal choroiditis with panuveitis represents a perivascular topographic phenotype within the multifocal choroiditis with panuveitis spectrum. Recognition of perivascular multifocal choroiditis with panuveitis may improve differentiation from vasculitic and inflammatory chorioretinal mimickers.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"1492-1504"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147943890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COMPARISON BETWEEN THIN AND THICK CHOROID EYES IN CENTRAL SEROUS CHORIORETINOPATHY.","authors":"Sanya Yadav, Nasiq Hasan, Niroj Sahoo, Arman Zarnegar, Jessica Cao, Avery Zhou, Stanley Saju, Charles C Wykoff, Priya Shah, Panisa Singhanetr, Elizabeth Rossin, Lorenzo Ferro Desideri, Felicia Hertkorn, Marion R Munk, Carmen Antia Rodriguez Fernandez, Luis A Barquet, Min Kim, Stela Vujosevic, Yusuf Ashfaq, Zachary Kroeger, Lorenzo Pili, Lisa Checchin, Maurizio B Parodi, Manjot Gill, Samer Khateb, Michael Zhang, Francisco Rodriguez, Peranut Chotcomwongse, Paisan Ruamviboonsuk, Adrian Fung, Jay Wang, Rahul N Khurana, Luiz H Lima, Lihteh Wu, Jay Chhablani","doi":"10.1097/IAE.0000000000004875","DOIUrl":"10.1097/IAE.0000000000004875","url":null,"abstract":"<p><strong>Purpose: </strong>While central serous chorioretinopathy is typically associated with pachychoroid, a subset of patients presents with thin choroids. This study aims to compare the clinical features of central serous chorioretinopathy in thin versus thick choroid eyes.</p><p><strong>Methods: </strong>In this retrospective multicenter study, patients were categorized by subfoveal choroidal thickness into thin (≤250 µ m) and thick (≥400 µ m) groups. Multimodal imaging was used to analyze central macular thickness, subfoveal choroidal thickness, neurosensory detachment height, Haller vessel thickness, and inner choroidal thickness at baseline and final visit.</p><p><strong>Results: </strong>Among 355 eyes, 52 (14.6%) had thin and 303 (85.4%) had thick choroids. Patients with thin choroids were older ( P < 0.001) and more often female (38.5% vs. 23.1%, P = 0.019). Visual acuity was similar at baseline (0.30 log minimum angle of resolution [logMAR], Snellen equivalent [20/40] versus 0.22 [20/33], and P = 0.38) and final (0.18 logMAR, Snellen equivalent [20/30] vs. 0.15 [20/28], and P = 0.08) follow-up. Central macular thickness decreased in both groups, but subfoveal choroidal thickness, Haller vessel thickness, and inner choroidal thickness remained stable in the thin group. Spontaneous resolution and recurrence rates were similar; however, choroidal neovascularization development was significantly higher in the thin choroid group ( P = 0.003).</p><p><strong>Conclusion: </strong>Thin-choroid central serous chorioretinopathy represents a distinct clinical phenotype with older age and female predominance. Although choroidal neovascularization occurred more frequently in this group compared with the thick choroid group, multivariate analysis indicates that age may be a key contributor to choroidal neovascularization risk.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"1570-1577"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PREOPERATIVE PROLIFERATIVE VITREORETINOPATHY IN OPEN-GLOBE INJURIES: Chronological Observations Based on the Inner Wound Tract Aspect.","authors":"Bingjie Wang, Kang Feng, Pei Zhang, Cong Liu, Yingyu Li, Ningning Chen, Ying Li, Yuntao Hu, Zhizhong Ma","doi":"10.1097/IAE.0000000000004844","DOIUrl":"10.1097/IAE.0000000000004844","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize chronological clinicopathological changes in the inner wound tract of Zone III open-globe injuries (OGIs) and clarify the early evolution of proliferative vitreoretinopathy (PVR).</p><p><strong>Methods: </strong>Patients with Zone III OGIs who underwent initial pars plana vitrectomy (PPV) were enrolled from the multicenter prospective Eye Injury Vitrectomy Study. Tissue from the inner wound tract was collected during surgery for hematoxylin and eosin and periodic acid-Schiff staining. PVR progression was further confirmed retrospectively from intraoperative videos.</p><p><strong>Results: </strong>Thirty-seven eyes were analyzed. Histopathology demonstrated a sequential course: initial inflammation and exudation, followed by fibroblast migration and fibrous membrane formation. Hemorrhagic clots progressively organized, replaced by fibrous tissue, and eventually evolved into scar tissue with declining cellularity. Retinal structures remained largely preserved within 14 days. Beyond this stage, thinning of the nuclear layer and vacuolar degeneration of the nerve fiber layer were evident. Thereafter, nuclear loss, disorganization, and loosening were observed in the retina, with compressed nuclei in regions adjacent to epimembranes. Clinically, proliferative activity appeared by 7 to 14 days and intensified after two weeks, coinciding with irreversible retinal remodeling.</p><p><strong>Conclusion: </strong>PVR develops rapidly after OGIs, with proliferative activity detectable within the first week and significant retinal disorganization after two weeks. Early PPV may preserve retinal integrity and limit progression, but acute-phase surgery faced technical risks, underscoring the need for individualized timing of intervention.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"1562-1569"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Lupus Erythematosus Associated Drusen-like Deposits.","authors":"Irmak Karaca, Tongalp H Tezel","doi":"10.1097/IAE.0000000000005005","DOIUrl":"https://doi.org/10.1097/IAE.0000000000005005","url":null,"abstract":"","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148867877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of foveal-involving tractional retinal detachments from proliferative diabetic retinopathy with intravitreal anti-VEGF therapy.","authors":"Nihaal Mehta, G Baker Hubbard","doi":"10.1097/IAE.0000000000005004","DOIUrl":"https://doi.org/10.1097/IAE.0000000000005004","url":null,"abstract":"<p><strong>Purpose: </strong>To report the outcomes of patients with fovea-off tractional retinal detachment (TRD) from proliferative diabetic retinopathy (PDR) treated with serial anti-VEGF therapy.</p><p><strong>Methods: </strong>We reviewed the medical records of patients with fovea-off TRD from PDR treated with serial anti-VEGF therapy. Outcome measures included visual acuity, foveal reattachment, need for vitrectomy, number of intravitreal injections, and average interval between injections.</p><p><strong>Results: </strong>12 eyes of 10 patients were included. 75% of eyes (n = 9) had foveal reattachment with anti-VEGF therapy alone. The average time from TRD diagnosis to foveal reattachment was 15 months. Patient who experienced foveal reattachment (n = 9) received an average of 7 injections with an average injection interval of 2.3 months. At presentation, mean logMAR VA was 1.79 (Snellen visual acuity equivalent 20/1233). At 6 months, mean logMAR VA was 1.6 (20/790), and at 12 months, mean logMAR VA was 1.4 (20/466). At a last follow-up (mean 27.8 months), mean logMAR VA was to 1.36 (20/453) among all patients and 1.01 (20/204) among patients who had foveal reattachment.</p><p><strong>Conclusion: </strong>In this cohort of eyes treated with intravitreal anti-VEGF for fovea-off TRD from PDR retinopathy, we observed visual and anatomic stability, and, in some cases, improvement.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148867924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}